title: Anti-diabetic effects of sodium 4-amino-2,6-dipicolinatodioxovanadium(V) dihydrate in streptozotocin-induced diabetic rats.
abstract: The evaluation of the anti-diabetic effects of an organic vanadium(V) complex in streptozotocin (STZ)-induced diabetic rats was investigated. The STZ-induced diabetic rats were orally administrated with sodium 4-amino-2,6-dipicolinatodioxovanadium(V) dihydrate (V5dipic-NH(2)), a vanadium(V) coordination compound. The compound was administered through drinking water at a concentration of 0.1mg/mL for 20 days, and then the concentration was increased to 0.3mg/mL for the following 20 days. At the end of the experiment, V5dipic-NH(2) statistically significantly reduced the levels of blood glucose (P<0.01), serum total cholesterol (P<0.01), triglycerides (P<0.01) and the activities of serum aspartate amino transferase (P<0.05) and alkaline phosphatase (P<0.01) compared to untreated diabetic animals. After treatment with 0.3mg/mL V5dipic-NH(2), the oral glucose tolerance was improved in diabetic animals (P<0.01). In addition, the daily intake of elemental vanadium was markedly decreased in V5dipic-NH(2)-treated diabetic rats compared to vanadyl sulfate (VOSO(4))-treated diabetic rats, which suggested that the anti-diabetic activity of the element vanadium was elevated after being modified with an organic ligand. These results suggested that V5dipic-NH(2), as an organic vanadium compound, is more effective than inorganic vanadium salt at alleviating the symptoms of diabetes.
authors.affiliation: College of Life Sciences, Graduate University of Chinese Academy of Sciences, No. 19A YuQuan Road, Beijing, China.
authors.forename: Ming
authors.initials: M
authors.lastname: Li
authors.forename: Jason J
authors.initials: JJ
authors.lastname: Smee
authors.forename: Wenjun
authors.initials: W
authors.lastname: Ding
authors.forename: Debbie C
authors.initials: DC
authors.lastname: Crans
mesh_terms: D000818:Animals; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D009942:Organometallic Compounds / Q000008:administration & dosage* / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin / Q000494:pharmacology; D013997:Time Factors; D017968:Vanadium Compounds / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D007004:Hypoglycemic Agents; D009942:Organometallic Compounds; D017968:Vanadium Compounds; C541655:sodium 4-amino-2,6-dipicolinatodioxovanadium(V) dihydrate; D013311:Streptozocin